Stock ALEC ALECTOR, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Alector, Inc.

Equities

ALEC

US0144421072

Market Closed - Nasdaq
Other stock markets
 21:00:00 30/04/2024 BST 		5-day change 1st Jan Change
5.08 USD -3.42% Intraday chart for Alector, Inc. -4.87% -36.34%
04-17 Certain Restricted Stock Units of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024. CI
04-17 Certain Options of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Certain Restricted Stock Units of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.
CI
Certain Options of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.
CI
Certain Common Stock of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.
CI
Alector, Inc. Announces Board Changes
CI
Transcript : Alector, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM
Alector to Participate in Upcoming Healthcare Conferences
GL
Transcript : Alector, Inc., 2023 Earnings Call, Feb 27, 2024
Alector: Q4 Earnings Snapshot
AQ
Alector, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Alector, Inc. Provides Revenue Guidance for the Year Ending 2024
CI
Alector, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GL
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
GL
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
GL
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
AQ
Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer?S Disease
CI
Alector, GSK Say FDA Grants Breakthrough Therapy Label For Frontotemporal Dementia Treatment
MT
GSK: breakthrough therapy status in dementia
CF
Alector, GSK Get FDA Breakthrough Designation for Latozinemab
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALEC Stock
  4. News Alector, Inc.